FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120044571> ?p ?o ?g. }

• W2120044571 endingPage "2555" @default.
• W2120044571 startingPage "2549" @default.
• W2120044571 abstract "Purpose Oxaliplatin-based chemotherapy can cause hepatic sinusoidal injury, with resultant sinusoidal damage and portal hypertension. We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia. Patients and Methods We retrospectively assessed the relationship between chemotherapy exposure, changes in spleen size (determined by volumetric measurements), and platelet counts in 136 patients treated with adjuvant fluorouracil and oxaliplatin (FOLFOX) or fluoropyrimidine for stage II or III colorectal adenocarcinoma. Hepatic sinusoidal injury and changes in spleen size were graded in a separate population of 63 patients with metastatic colorectal cancer receiving fluoropyrimidine and oxaliplatin before liver resection. Results Spleen size increased in 86% of patients treated with adjuvant FOLFOX (P < .001), with a ≥ 50% increase in 24% of patients. Spleen size did not significantly increase in patients treated with adjuvant fluoropyrimidine. Increases in spleen size correlated with cumulative oxaliplatin dose (P = .003). Patients with splenic enlargement ≥ 50% had higher rates of thrombocytopenia in the first year after completion of chemotherapy (27% v 5%; P = .003). In patients with hepatic metastases treated with preoperative fluoropyrimidine and oxaliplatin, increases in spleen size was a predictor of higher histologic grades of sinusoidal injury in both univariate (P = .03) and multivariate (P = .02) analyses. Conclusion Increases in spleen size correlate with increasing grade of hepatic sinusoidal injury and can serve as a simple method for identifying patients at risk for this toxicity. Oxaliplatin-induced increases in spleen size should be recognized as a potential etiology of persistent thrombocytopenia after oxaliplatin treatment." @default.
• W2120044571 created "2016-06-24" @default.
• W2120044571 creator A5003827387 @default.
• W2120044571 creator A5006348751 @default.
• W2120044571 creator A5009132832 @default.
• W2120044571 creator A5021400647 @default.
• W2120044571 creator A5035371911 @default.
• W2120044571 creator A5036824275 @default.
• W2120044571 creator A5045206466 @default.
• W2120044571 creator A5052650376 @default.
• W2120044571 creator A5062181429 @default.
• W2120044571 creator A5072207853 @default.
• W2120044571 creator A5085656655 @default.
• W2120044571 date "2010-05-20" @default.
• W2120044571 modified "2023-10-18" @default.
• W2120044571 title "Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury" @default.
• W2120044571 cites W1973662511 @default.
• W2120044571 cites W1974913186 @default.
• W2120044571 cites W1981845767 @default.
• W2120044571 cites W1988804148 @default.
• W2120044571 cites W1991939907 @default.
• W2120044571 cites W1992037154 @default.
• W2120044571 cites W2001786662 @default.
• W2120044571 cites W2003411964 @default.
• W2120044571 cites W2003437905 @default.
• W2120044571 cites W2015155974 @default.
• W2120044571 cites W2024252755 @default.
• W2120044571 cites W2025410458 @default.
• W2120044571 cites W2036138453 @default.
• W2120044571 cites W2043103956 @default.
• W2120044571 cites W2048398534 @default.
• W2120044571 cites W2052788412 @default.
• W2120044571 cites W2053559979 @default.
• W2120044571 cites W2055235876 @default.
• W2120044571 cites W2062501613 @default.
• W2120044571 cites W2072899950 @default.
• W2120044571 cites W2078345568 @default.
• W2120044571 cites W2084954217 @default.
• W2120044571 cites W2111152466 @default.
• W2120044571 cites W2112727687 @default.
• W2120044571 cites W2120268483 @default.
• W2120044571 cites W2131745440 @default.
• W2120044571 cites W2138235363 @default.
• W2120044571 cites W2139738991 @default.
• W2120044571 cites W2140407914 @default.
• W2120044571 cites W2143007780 @default.
• W2120044571 cites W2154143304 @default.
• W2120044571 cites W2166608843 @default.
• W2120044571 cites W2166667674 @default.
• W2120044571 cites W2171232394 @default.
• W2120044571 doi "https://doi.org/10.1200/jco.2009.27.5701" @default.
• W2120044571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20406923" @default.
• W2120044571 hasPublicationYear "2010" @default.
• W2120044571 type Work @default.
• W2120044571 sameAs 2120044571 @default.
• W2120044571 citedByCount "183" @default.
• W2120044571 countsByYear W21200445712012 @default.
• W2120044571 countsByYear W21200445712013 @default.
• W2120044571 countsByYear W21200445712014 @default.
• W2120044571 countsByYear W21200445712015 @default.
• W2120044571 countsByYear W21200445712016 @default.
• W2120044571 countsByYear W21200445712017 @default.
• W2120044571 countsByYear W21200445712018 @default.
• W2120044571 countsByYear W21200445712019 @default.
• W2120044571 countsByYear W21200445712020 @default.
• W2120044571 countsByYear W21200445712021 @default.
• W2120044571 countsByYear W21200445712022 @default.
• W2120044571 countsByYear W21200445712023 @default.
• W2120044571 crossrefType "journal-article" @default.
• W2120044571 hasAuthorship W2120044571A5003827387 @default.
• W2120044571 hasAuthorship W2120044571A5006348751 @default.
• W2120044571 hasAuthorship W2120044571A5009132832 @default.
• W2120044571 hasAuthorship W2120044571A5021400647 @default.
• W2120044571 hasAuthorship W2120044571A5035371911 @default.
• W2120044571 hasAuthorship W2120044571A5036824275 @default.
• W2120044571 hasAuthorship W2120044571A5045206466 @default.
• W2120044571 hasAuthorship W2120044571A5052650376 @default.
• W2120044571 hasAuthorship W2120044571A5062181429 @default.
• W2120044571 hasAuthorship W2120044571A5072207853 @default.
• W2120044571 hasAuthorship W2120044571A5085656655 @default.
• W2120044571 hasBestOaLocation W21200445711 @default.
• W2120044571 hasConcept C121608353 @default.
• W2120044571 hasConcept C126322002 @default.
• W2120044571 hasConcept C2776694085 @default.
• W2120044571 hasConcept C2778260052 @default.
• W2120044571 hasConcept C2780931953 @default.
• W2120044571 hasConcept C2780962732 @default.
• W2120044571 hasConcept C526805850 @default.
• W2120044571 hasConcept C71924100 @default.
• W2120044571 hasConcept C90924648 @default.
• W2120044571 hasConceptScore W2120044571C121608353 @default.
• W2120044571 hasConceptScore W2120044571C126322002 @default.
• W2120044571 hasConceptScore W2120044571C2776694085 @default.
• W2120044571 hasConceptScore W2120044571C2778260052 @default.
• W2120044571 hasConceptScore W2120044571C2780931953 @default.
• W2120044571 hasConceptScore W2120044571C2780962732 @default.
• W2120044571 hasConceptScore W2120044571C526805850 @default.
• W2120044571 hasConceptScore W2120044571C71924100 @default.

• next